Olympus Corporation

Olympus Corporation

OLYMY
Olympus CorporationUS flagOther OTC
10.53
USD
-0.24
- -
11.19BMarket Cap
Olympus Corporation
OLYMY
(Other OTC)

Recent

price

10.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
788.27
794.84
671.45
537.12
558.58
587.74
540.97
574.88
581.3
575.51
568.25
584.7
696.16
762.96
871.54
909.06
434.56
Revenue per Share
3.6
-45.88
7.24
10.26
-6.38
45.72
31.25
41.71
5.97
39.37
10.05
90.22
113.22
199.91
102.99
61.32
36.31
Basic EPS, GAAP
0.79
-4.08
-2.47
29.97
18.78
-5.69
30.57
23.2
4.01
51.52
50.48
84.15
22
-18.34
109.46
16.34
31.69
Free Cash Flow per Basic Share
7.54
3.75
- -
- -
- -
2.5
4.25
7
7
7.81
10
12.03
14.07
16.53
18.33
20.29
- -
Dividend per Share
150.62
56.39
61.38
61.4
83.14
185.19
226.27
264.51
265.72
305.17
313.38
334.94
391.29
509.36
476.79
491.98
- -
Book Value per Share
-84.12
-139.68
-20.49
118.77
129.01
135.47
164.22
200.04
199.12
151.52
127.01
176.55
270.87
399.62
416.98
464.81
- -
Tangible Book Value per Share
1,075
1,068
1,108
1,328
1,369
1,369
1,369
1,368
1,366
1,312
1,286
1,283
1,267
1,213
1,144
1,112
1,150
Basic Weighted Avg Shares
847,105
848,548
743,851
713,286
764,671
804,578
740,557
786,497
793,862
755,231
730,544
750,123
881,923
925,752
997,332
1,010,676
499,704
Sales/Revenue/Turnover
4.53
4.19
4.72
10.3
11.9
12.98
9.78
10.31
3.49
12.14
11.14
19.29
21.1
5.59
16.24
9.98
9.5
Operating Margin (%)
46,437
46,070
43,582
46,307
50,640
49,779
54,290
52,913
58,669
68,309
59,937
64,615
66,741
65,940
66,456
67,216
16,805
Depreciation Expense
3,866
-48,985
8,020
13,627
-8,737
62,594
42,783
57,064
8,147
51,670
12,918
115,742
143,432
242,566
117,855
68,172
41,749
Net Income, GAAP
78.37
- -
56.94
17.04
199.29
11.51
31.48
25.53
59.99
30.06
14.5
21.93
24.3
19.6
25.94
27.47
18.7
Effective Tax Rate (%)
0.46
-5.77
1.08
1.91
-1.14
7.78
5.78
7.26
1.03
6.84
1.77
15.43
16.26
26.2
11.82
6.75
8.35
Profit Margin (%)
200,762
206,165
224,177
300,206
202,735
190,941
219,297
208,371
168,521
172,937
251,682
318,354
264,465
368,645
254,192
269,434
- -
Working Capital
521,252
530,311
422,880
346,814
253,286
263,731
217,193
159,183
121,628
199,897
323,735
333,846
290,087
229,628
134,117
159,700
- -
LT Debt
115,579
48,028
151,907
331,284
357,254
366,582
396,228
444,259
442,387
371,958
395,480
511,362
641,234
757,186
751,733
812,040
- -
Total Equity
0.99
- -
2.12
8.2
-12.17
13.02
7.14
8.65
1.66
9.9
9.76
13.34
14
3.82
11.32
6.95
- -
Return on Invested Capital (%)
0.73
- -
2.06
4.09
-3.6
13.31
8.56
10.31
2.14
9.25
2.54
15.23
18.07
28.55
14.53
9.6
6.92
Return on Capital (%)
2.04
-44.12
12.51
18.23
-8.94
34.08
15.19
16.99
2.25
13.54
3.22
27.8
31
43.56
20.26
12.48
11.75
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
114,936
- -
LT Borrowings
- -
130,546
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,144
- -
Market Capitalization
3,119,640
3,196,738
2,690,362

Working Capital

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
657,065
- -
Cash, Cash Equivalents & STI
- -
274,891
- -
Accounts Receivable, Net
- -
166,830
- -
Inventories
- -
187,843
- -
Total Current Liabilities
- -
419,575
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
114,936
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.03%
16.02%
8.02%
Free Cash Flow
-54.96%
-187.18%
-85.5%
Net Income, GAAP
117.07%
159.09%
-42.16%
Sales/Revenue/Turnover
2.53%
6.86%
1.34%
Total Cash Common Dividend
22.73%
12.04%
7.51%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
207,723
226,608
239,070
260,496
925,752
2025
- -
239,208
- -
- -
997,332
2026
- -
247,838
- -
- -
1,010,676

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
191.9
-19.64
15.84
- -
199.91
2025
- -
29.82
- -
- -
102.99
2026
- -
18.09
- -
- -
61.32

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
- -
- -
- -
16.53
2025
- -
- -
- -
- -
18.33
2026
- -
- -
- -
- -
20.29
Business
Olympus Corporation, a global medical technology and scientific imaging company, designs, manufactures, and markets endoscopy systems, optical and precision imaging devices, therapeutic and surgical instruments, and related imaging solutions for healthcare, life sciences, and industrial applications. The company operates across multiple value chains including medical endoscopy; diagnostic imaging systems; minimally invasive surgical devices; scientific and industrial imaging, microscopes and cameras; and associated services such as clinical support, education, and maintenance. MANDATORY MAIN PRODUCTS AND SERVICES: Endoscopy solutions including endoscopes, video imaging systems, and ancillary imaging platforms; Advanced diagnostic imaging and therapeutic devices for minimally invasive procedures; Surgical instruments and accessories for endoscopic and laparoscopic applications; Medical imaging systems, optics and precision components; Scientific and industrial imaging products including microscopes, cameras, image analysis tools, and related software; Industrial and consumer imaging brands and related technical services; Clinical education, training, and customer support services. LATEST MAJOR COMPANY CHANGES: Strategic refocusing toward intelligent endoscopy ecosystems, including AI-driven imaging and cloud-enabled platforms; Expansion of AI-powered endoscopy solutions and digital health initiatives through global partnerships and regional regional centers of excellence; Organizational simplification to improve agility and investment in next-generation medical technologies; Ongoing collaborations with technology and healthcare partners to accelerate development of integrated care platforms; Continued expansion of product lines and geographic footprint through partnerships, acquisitions, or joint ventures within the medical technology sector. ADDITIONAL CONTEXT: Industry: Medical devices, diagnostic imaging, life sciences, and industrial imaging; Business segments include Endoscopy, Medical Systems, Scientific Solutions, and Industrial Imaging; Target markets comprise hospitals, clinics, research laboratories, and industrial users; Geographic operations span Asia-Pacific, the Americas, Europe, Middle East, and Africa, with headquarters in Tokyo, Japan; Founded in 1919, Olympus operates as a global group with subsidiaries and regional affiliates, including Olympus America and Olympus Europe, under a shared corporate strategy.

Company News

APIChatGPT
  • Olympus Corporation (OLYMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • Olympus (OTCMKTS:OCPNY) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

  • Olympus Corporation (OLYMY) Discusses New Strategic Vision and Expansion of Endoscopy-Enabled Care Prepared Remarks Transcript

  • Olympus Corporation (OLYMY) Q1 2026 Earnings Call Transcript

  • Trends Shaping Qatar's Infection Control Market 2025-2034: Featuring Sidra Medicine, BD, Condair, Sotera Health, Olympus, 3M

  • North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

  • North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key Companies - Boston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf

  • Apollo Announces Olympus Housing Capital

  • Olympus Corporation (OLYMY) Q4 2025 Earnings Call Transcript

  • Olympian Motors and Foxconn Partner to Launch Olympus OS: AI-Defined Vehicle Operating System

  • Monroe Capital Supports Olympus Partners' Acquisition of PAI Pharma

  • Monroe Capital Supports Olympus Partners' Acquisition of Accelevation Holding Company, LLC

  • Olympus Corporation (OLYMY) Q3 2025 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Q2 2025 Earnings Call Transcript

  • Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility

  • Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available

  • Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment

  • Olympus Corporation (OCPNY) Q3 2022 Earnings Call Transcript

  • OCPNY or EW: Which Is the Better Value Stock Right Now?

  • What Makes Olympus Corp. (OCPNY) a Good Fit for "Trend Investing"